Evidence map›Paper›PMID 39687184›Full record

ArticleHeliyon2024

Molecular diagnostics using the QIAstat-Dx syndromic device for covering avian influenza pandemic preparedness.

Luis Peñarrubia, Sven Reister, Sara Jiménez-Guzmán, Roberto Porco, Clàudia Congost-Teixidor, Gemma Pueyo, Carla Camprubí-Font, Katariina Vara, Maria de la Cruz Cardenosa, Maria Contreras and 7 more

Abstract read
In one paragraph

Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Luis PeñarrubiaSTAT-Dx Life S.L. (A QIAGEN Company) Baldiri Reixac, 4 Barcelona 08028, Spain.
Sven ReisterQIAGEN GmbH, Qiagenstr.1 40724 Hilden, Germany.
Sara Jiménez-GuzmánSTAT-Dx Life S.L. (A QIAGEN Company) Baldiri Reixac, 4 Barcelona 08028, Spain.
Roberto PorcoSTAT-Dx Life S.L. (A QIAGEN Company) Baldiri Reixac, 4 Barcelona 08028, Spain.
Clàudia Congost-TeixidorSTAT-Dx Life S.L. (A QIAGEN Company) Baldiri Reixac, 4 Barcelona 08028, Spain.
Gemma PueyoSTAT-Dx Life S.L. (A QIAGEN Company) Baldiri Reixac, 4 Barcelona 08028, Spain.
Carla Camprubí-FontSTAT-Dx Life S.L. (A QIAGEN Company) Baldiri Reixac, 4 Barcelona 08028, Spain.
Katariina VaraSTAT-Dx Life S.L. (A QIAGEN Company) Baldiri Reixac, 4 Barcelona 08028, Spain.
Maria de la Cruz CardenosaSTAT-Dx Life S.L. (A QIAGEN Company) Baldiri Reixac, 4 Barcelona 08028, Spain.
Maria ContrerasSTAT-Dx Life S.L. (A QIAGEN Company) Baldiri Reixac, 4 Barcelona 08028, Spain.
Aida MayorgasSTAT-Dx Life S.L. (A QIAGEN Company) Baldiri Reixac, 4 Barcelona 08028, Spain.
Frederick van DeursenQIAGEN Manchester Ltd, Citylabs 2.0, Hathersage Road, Manchester, M13 0BH, UK.
Dietrich LueerssenSTAT-Dx Life S.L. (A QIAGEN Company) Baldiri Reixac, 4 Barcelona 08028, Spain.
Marti Juanola-FalgaronaSTAT-Dx Life S.L. (A QIAGEN Company) Baldiri Reixac, 4 Barcelona 08028, Spain.
Martin SchwemmleInstitute of Virology, Medical Center University of Freiburg, Freiburg, Germany.
Kevin CiminskiInstitute of Virology, Medical Center University of Freiburg, Freiburg, Germany.
Davide ManisseroQIAGEN Manchester Ltd, Citylabs 2.0, Hathersage Road, Manchester, M13 0BH, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: A key factor in influenza pandemic preparedness is the ability to detect zoonotic influenza virus strains as they emerge in humans through spillover events, ideally before human-to-human transmission occurs. Design: In this study, the utility of the QIAstat-Dx syndromic device for influenza surveillance was evaluated. Bioinformatic analysis was performed on all WHO-recommended influenza Candidate Vaccine Viruses (CVVs), including the common strains recommended for the 2023-2024 influenza vaccine composition in the northern hemisphere, and 16 different H5 highly pathogenic avian influenza virus (HPAIV) and two H9N2 low pathogenic avian influenza virus (LPAIV) strains. For laboratory validation, engineered gene fragments and real HPAIV and LPAIV samples were tested using the QIAstat-Dx Respiratory SARS-CoV-2 Panel. Results: During the bioinformatic screening, common influenza strains were positive including influenza A subtypes, and all H5 HPAIV and LPAIV H9N2 were detected as Influenza A positive without subtype discrimination. In all cases, laboratory validation confirmed all bioinformatic results. Conclusion: QIAstat-Dx can detect all tested potentially zoonotic influenza A virus strains, and discriminate them from human sesonal influenza A viruses, ensuring a correct diagnosis. Any tool available for surveillance and pandemic preparedness is essential for a rapid response to reduce healthcare costs and severity of future influenza pandemics.

Indexed as

High pathogenic avian influenzaInfluenza a H5 detectionInfluenza pandemic preparednessInfluenza surveillanceQIAstat-dx respiratory SARS-CoV-2 panel

Identifiers

PMID39687184
PMCPMC11647833

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.